BMS reports liver injury events in lung disease program, with key readout near
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.
BMS reports liver injury events in lung disease program, with key readout near Read More »
